VASCULAR ACCESS MANAGEMENT

SorbaView® SHIELD

The most secure catheter stabilization dressing.
Request product sample

Reduce CABSIs and related costs

SorbaView® SHIELD multi-layer dressing and catheter securement device provides an integrated design that reduces the rate of unscheduled restarts for IVs and complications such as phlebitis, extravasation and infiltration and reduces the risk of catheter-associated bloodstream infection (CABSI). It also eliminates the cost of a secondary securement device.

5x

Readmittance is five times more likely for CABSI patients1

25%

Patient mortality rate with CABSI ranges from 12 to 25 percent2

Built-in securement helps reduce risk of infection and complications

SorbaView® SHIELD offers a comfortable, breathable barrier against external bacteria, while also withstanding multi-directional tugging forces. Our design helps prevent the dressing from coming loose, which can expose the line to contaminants. This one-step dressing and securement device stays securely in place for long wear times—up to 7 days for central lines and for 96 hours or until clinically indicated for peripheral catheters.

Click the icons below to explore

2021 INS guidelines expand recommendations for integrated securement products

The latest version of the Infusion Nurses Society (INS) Infusion Therapy Standards of Practice state that inadequate vascular access device (VAD) securement creates risk for clinically significant complications that could result in premature device removal.3

65%–70%

Percentage of CABSIs that may be preventable with evidence-based practices 4

Request product sample

Simply complete this form, and a Medline Representative will contact you.

Make CLABSI prevention second nature

Explore our full Vascular Access Management Solution. From best practice guidance and education to the right system of products, we help you drive a culture of safety across your organization.

Learn more

REFERENCES:
1. Khong C, Baggs, J, Kleinbaum D, Cochran R, Jernigan JA. The likelihood of hospital readmission among patients with hospital-onset central line-associated bloodstream infections. Infect Control Hosp Epidemiol. 2015; 36(8): 886–892. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702248/.
2. Agency for Healthcare Research and Quality. Eliminating CLABSI, A National Patient Safety Imperative: Final Report Companion Guide. Available at: https://www.ahrq.gov/hai/cusp/clabsi-final-companion/clabsicomp4c.html.
3. Gorski LA et al. Infusion Therapy Standards of Practice. Journal of Infusion Nursing. 2021; 44(15). Available at: https://gavecelt.it/nuovo/sites/default/files/uploads/Infusion%20Therapy%20Standards%20of%20Practice%202021.pdf.
4. The Joint Commission. Preventing Central Line-Associated Bloodstream Infections: A Global Challenge, A Global Perspective. Available at: https://www.jointcommission.org/assets/1/18/CLABSI_Monograph.pdf.